ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Ikena, Senti and others look to clinical presentations at AACR.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
